孟鲁司特钠联合盐酸西替利嗪治疗咳嗽变异性哮喘儿童的临床观察 |
| |
引用本文: | 陈丙文,陈斌斌,石泽真. 孟鲁司特钠联合盐酸西替利嗪治疗咳嗽变异性哮喘儿童的临床观察[J]. 西北药学杂志, 2016, 0(3): 308-310. DOI: 10.3969/j.issn.1004-2407.2016.03.026 |
| |
作者姓名: | 陈丙文 陈斌斌 石泽真 |
| |
作者单位: | 广东省深圳市宝安区中心医院儿科,深圳,518102 |
| |
基金项目: | 广东省深圳市宝安区科技计划项目(编号2013235) |
| |
摘 要: | ![]() 目的探讨孟鲁司特钠联合盐酸西替利嗪对咳嗽变异性哮喘(CVA)儿童临床症状的改善作用,并评估其对肺功能的影响。方法选择CVA儿童104例,随机平均分为观察组和对照组,观察组应用孟鲁司特钠联合盐酸西替利嗪进行治疗;对照组给予常规治疗。评估2组患者日间、夜间咳嗽症状及睡眠状况,观察主要症状、体征消失和改善时间,并评估其肺功能。结果观察组患者治疗后日间咳嗽、夜间咳嗽及匹兹堡睡眠质量指数(PSQI)评分分别为1.12±0.29,1.10±0.33和11.14±1.02分,均低于治疗后对照组(P<0.05);观察组患者退热时间、咳嗽消失时间、呼吸困难消失时间和胸片恢复时间分别为3.20±0.31,7.40±0.69,8.17±0.66和8.65±0.71d,均低于对照组(P<0.05)。观察组患者治疗后FEV1、FEV1/FVC和PEF pred%分别为1.74±0.35L,83.22%±7.26%和11.14%±1.02%,均高于对照组(P<0.05)。结论孟鲁司特钠联合盐酸西替利嗪治疗CVA儿童,能够显著改善患儿临床症状,缩短症状或体征改善时间,提高其肺功能。
|
关 键 词: | 孟鲁司特钠 盐酸西替利嗪 咳嗽变异性哮喘(CVA) 儿童 肺功能 |
Observation of montelukast sodium combined with cetirizine hydrochloride for the treatment of children with cough variant asthma |
| |
Abstract: | ![]() Objective To explore the improvement method on clinical symptoms of montelukast sodium combined with cetirizine hydrochloride for the children with cough variant asthma(CVA) and assess their lung function .Methods 104 cases of CVA chil‐dren were selected and they were randomly divided into the observation group and the control group .The observation group were given montelukast sodium with cetirizine hydrochloride therapy ,while the control group were given routine treatment .The cough at night and day ,sleep situation ,the main signs or symptoms ,and the lung function were observed .Results The cough at night and day ,pittsburgh sleep quality index (PSQI) score after the treatment were 1 .12 ± 0 .29 ,1 .10 ± 0 .33 and 11 .14 ± 1 .02 points , lower than that of the control group ,The two groups after treatment was lower than before treatment (P< 0 .05) .The fever , cough disappeared time ,breathing difficulty and chest radiograph recovery time of the observation group were 3 .20 ± 0 .31 ,7 .40 ± 0 .69 ,8 .17 ± 0 .66 and 8 .65 ± 0 .71 d ,lower than that of the control group (P<0 .05) .FEV1 ,FEV1/FVC and PEF pred% of the observation group after treatment was 1 .74 ± 0 .35 L ,83 .22% ± 7 .26% and 11 .14% ± 1 .02% ,higher than that of the control group (P<0 .05) .Conclusion Montelukast sodium combined with cetirizine hydrochloride for the treatment of CVA children can significantly improve the clinical symptoms ,shorten the time of signs or symptoms ,and improve the lung function . |
| |
Keywords: | montelukast sodium cetirizine hydrochloride cough variant asthma(CVA) children lung function |
本文献已被 万方数据 等数据库收录! |
|